P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV

The p21 participates in the regulation of DNA repair and replication, and modulation of apoptosis as well. After DNA damage, the p53-dependent induction of p21 results in cell cycle arrest or could trigger cell apoptosis. The objective of the study was the assessment of p21 immunoreactivity in recta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Monika A. Kozłowska-Geller, Stanisław Z. Głuszek, Piotr Lewitowicz
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2021
Materias:	rectal cancer p21 immuno-histochemistry. Medicine R
Acceso en línea:	https://doaj.org/article/ea8580fb816946b0a1a57eb5ec9b5c87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea8580fb816946b0a1a57eb5ec9b5c87
record_format	dspace
spelling	oai:doaj.org-article:ea8580fb816946b0a1a57eb5ec9b5c872021-12-02T19:19:18ZP21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV1428-25261897-430910.5114/wo.2020.102632https://doaj.org/article/ea8580fb816946b0a1a57eb5ec9b5c872021-01-01T00:00:00Zhttps://www.termedia.pl/P21-is-not-a-prognostic-marker-for-rectal-cancer-five-year-follow-up-study-of-rectal-cancer-in-stages-I-IV,3,42985,1,1.htmlhttps://doaj.org/toc/1428-2526https://doaj.org/toc/1897-4309The p21 participates in the regulation of DNA repair and replication, and modulation of apoptosis as well. After DNA damage, the p53-dependent induction of p21 results in cell cycle arrest or could trigger cell apoptosis. The objective of the study was the assessment of p21 immunoreactivity in rectal cancer and the estimation of relationships with clinical outcome especially as predictor of poor outcome. While applying the ruling in and out criteria, 102 patients were incorporated to the study, with stage I–IV rectal cancer who had undergone surgery in a planned mode during 2005–2011. The follow-up covered 5 years period from surgery date. Conventional immunohistochemistry were performed using antibody against p21 (p21WAF1 (Clone H252) to detect overexpression targeted receptor. The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0; 1; 2; 3 (p = 0.6453 in the log-rank test), also is not a significant risk factor for death (HR = 0.915, p = 0.7842) and for tumor dissemination (HR = 0.94, p = 0.9426). Our study leads to the conclusion that the probability of survival does not depend on p21 expression and do not authorize the importance of p21 immunoreactivity in the detection and monitoring of rectal cancer treatment.Monika A. Kozłowska-GellerStanisław Z. GłuszekPiotr LewitowiczTermedia Publishing Housearticlerectal cancer p21 immuno-histochemistry.MedicineRENContemporary Oncology, Vol 24, Iss 4, Pp 247-251 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rectal cancer p21 immuno-histochemistry. Medicine R
spellingShingle	rectal cancer p21 immuno-histochemistry. Medicine R Monika A. Kozłowska-Geller Stanisław Z. Głuszek Piotr Lewitowicz P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
description	The p21 participates in the regulation of DNA repair and replication, and modulation of apoptosis as well. After DNA damage, the p53-dependent induction of p21 results in cell cycle arrest or could trigger cell apoptosis. The objective of the study was the assessment of p21 immunoreactivity in rectal cancer and the estimation of relationships with clinical outcome especially as predictor of poor outcome. While applying the ruling in and out criteria, 102 patients were incorporated to the study, with stage I–IV rectal cancer who had undergone surgery in a planned mode during 2005–2011. The follow-up covered 5 years period from surgery date. Conventional immunohistochemistry were performed using antibody against p21 (p21WAF1 (Clone H252) to detect overexpression targeted receptor. The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0; 1; 2; 3 (p = 0.6453 in the log-rank test), also is not a significant risk factor for death (HR = 0.915, p = 0.7842) and for tumor dissemination (HR = 0.94, p = 0.9426). Our study leads to the conclusion that the probability of survival does not depend on p21 expression and do not authorize the importance of p21 immunoreactivity in the detection and monitoring of rectal cancer treatment.
format	article
author	Monika A. Kozłowska-Geller Stanisław Z. Głuszek Piotr Lewitowicz
author_facet	Monika A. Kozłowska-Geller Stanisław Z. Głuszek Piotr Lewitowicz
author_sort	Monika A. Kozłowska-Geller
title	P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
title_short	P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
title_full	P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
title_fullStr	P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
title_full_unstemmed	P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV
title_sort	p21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages i–iv
publisher	Termedia Publishing House
publishDate	2021
url	https://doaj.org/article/ea8580fb816946b0a1a57eb5ec9b5c87
work_keys_str_mv	AT monikaakozłowskageller p21isnotaprognosticmarkerforrectalcancerfiveyearfollowupstudyofrectalcancerinstagesiiv AT stanisławzgłuszek p21isnotaprognosticmarkerforrectalcancerfiveyearfollowupstudyofrectalcancerinstagesiiv AT piotrlewitowicz p21isnotaprognosticmarkerforrectalcancerfiveyearfollowupstudyofrectalcancerinstagesiiv
_version_	1718376887484416000

P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV

Ejemplares similares